ABSTRACT: Cardiac thromboembolism attributed to atrial fibrillation (AF) is responsible for up to one-third of ischemic strokes. Stroke may be the first manifestation of previously undetected AF. Given the efficacy of oral anticoagulants in preventing AF-related ischemic strokes, strategies of searching for AF after a stroke using ECG monitoring followed by oral anticoagulation (OAC) treatment have been proposed to prevent recurrent cardioembolic strokes. This white paper by experts from the AF-SCREEN International Collaboration summarizes existing evidence and knowledge gaps on searching for AF after a stroke by using ECG monitoring. New AF can be detected by routine plus intensive ECG monitoring in approximately one-quarter of patients with ischemic stroke. It may be causal, a bystander, or neurogenically induced by the stroke. AF after a stroke is a risk factor for thromboembolism and a strong marker for atrial myopathy. After acute ischemic stroke, patients should undergo 72 hours of electrocardiographic monitoring to detect AF. The diagnosis requires an ECG of sufficient quality for confirmation by a health professional with ECG rhythm expertise. AF detection rate is a function of monitoring duration and quality of analysis, AF episode definition, interval from stroke to monitoring commencement, and patient characteristics including old age, certain ECG alterations, and stroke type. Markers of atrial myopathy (eg, imaging, atrial ectopy, natriuretic peptides) may increase AF yield from monitoring and could be used to guide patient selection for more intensive/prolonged poststroke ECG monitoring. Atrial myopathy without detected AF is not currently sufficient to initiate OAC. The concept of embolic stroke of unknown source is not proven to identify patients who have had a stroke benefitting from empiric OAC treatment. However, some embolic stroke of unknown source subgroups (eg, advanced age, atrial enlargement) might benefit more from non–vitamin K-dependent OAC therapy than aspirin. Fulfilling embolic stroke of unknown source criteria is an indication neither for empiric non–vitamin K-dependent OAC treatment nor for withholding prolonged ECG monitoring for AF. Clinically diagnosed AF after a stroke or a transient ischemic attack is associated with significantly increased risk of recurrent stroke or systemic embolism, in particular, with additional stroke risk factors, and requires OAC rather than antiplatelet therapy. The minimum subclinical AF duration required on ECG monitoring poststroke/transient ischemic attack to recommend OAC therapy is debated.
Cardiac thromboembolism attributed to atrial fibrillation (AF) is responsible for up to one-third of ischemic strokes. The proportion increases with age, with an apparent secular trend to increasing prevalence. AF-related strokes are more frequently fatal or disabling and have a higher risk of institutionalization in comparison with ischemic strokes from other causes. Patients with AF-related strokes are older and more likely are women than those experiencing strokes without AF.

For between 11.5% and 24% of all patients with ischemic stroke or transient ischemic attack (TIA), the stroke/TIA is the first clinical documentation of AF. It is uncovered either on the admission ECG or by ECG monitoring after a stroke. In addition, the majority of AF-related strokes can be prevented by oral anticoagulation (OAC). These observations have been the rationale behind calls to search for undetected AF after a stroke and before a stroke to prevent a recurrent or first ischemic stroke. After the occurrence of ischemic stroke, the need to search for AF becomes even more obvious to start optimal secondary prevention. Direct evidence on the benefits of OAC initiation in patients with a poststroke AF diagnosis is limited. However, prior stroke in patients who are found to have clinical AF is one of the most powerful predictors of a recurrent stroke and has been incorporated in the CHA2DS2-VASc (congestive heart failure, hypertension, age category, diabetes, stroke/TIA/systemic embolism history, sex, vascular disease history) score with 2 points.

Searching for unknown AF after a stroke requires a defined process of using ECG monitoring of variable intensity and duration. An overview of poststroke AF monitoring studies is provided in Table I in the online-only Data Supplement. Variations in the proportion of newly identified AF after a stroke are related to timing, duration, and method of ECG monitoring, patient selection, and the probability of AF being detected before a stroke, which has likely increased in recent years. In patients free of AF who presented with a stroke or TIA, a stepwise approach to searching for AF using resting ECG, followed by Holter monitoring, and, later, 7-day external loop recorders, the AF detection rate was 14.8%. The estimated overall yield of AF detection across heterogeneous studies will result in a new AF diagnosis in 23.7% (95% CI, 17.2–31.0) of all patients after a stroke, 11.5% (95% CI, 8.9–14.3) in a smaller earlier meta-analysis. The heterogeneity of these data is obvious, highlighting the evolving nature of the information available to guide patient selection and ECG monitoring intensity in survivors of a stroke.

In this white paper, we summarize existing evidence and knowledge gaps on poststroke AF monitoring compiled by experts in the field. Key points do not reproduce guidelines or formal recommendations but rather provide consensus formulations of the AF-SCREEN International Collaboration that may help with a better understanding of the complex situation and uncertainties about searching for AF after a stroke and provide support for decision making in clinical practice. There is no uniformly used term for searching for AF after a stroke by ECG monitoring, but it is different from population screening in asymptomatic individuals. To call it screening for AF may therefore not be appropriate. Prior reviews and meta-analyses applied the terms “diagnosis,” “monitoring,” or “detection” of AF. The AF-SCREEN International Collaboration proposes the term “searching for AF” in secondary prevention. This implies an active, targeted process, requiring a poststroke AF search and electrocardiographic monitoring. These latter terms will therefore be used in the white paper.

PATHOPHYSIOLOGY OF STROKE IN AF

AF occurs when electrophysiological triggers act on a vulnerable atrial substrate, eg, an atrial myopathy determined by genetic, age-, lifestyle-, and disease-related dysfunction. Atrial myopathy can be a manifestation of a more general cardiomyopathy. Once AF begins, it leads to further atrial remodeling, thus worsening atrial cardiomyopathy. It is well established that fibrillation of the atria causes blood stasis, endothelial dysfunction, hypercoagulability, systemic inflammation, and thus an increased risk of thromboembolism. Change in rhythm from AF to sinus, whether spontaneous or through cardioversion, temporarily increases the risk of cardioembolic stroke.

There are alternative hypotheses for AF occurrence after a stroke. In one, AF may be just an innocent bystander. Given the shared cardiovascular risk factors, in particular, older age, stroke and AF may coincide in patients with concurrent small and large vessel atherosclerosis in the brain and cervicocranial vasculature. In those cases, AF may be only a comorbidity. This hypothesis is supported by the finding that, in ≈15% of all strokes with prevalent AF, the stroke etiology does not appear to be secondary to AF, and maintenance of sinus rhythm by a rhythm control strategy does not necessarily show a strong reduction in stroke rate. Whether maintenance of sinus rhythm by a rhythm control strategy in AF is associated with a reduction in stroke rate has not been proven by a prospective randomized controlled trial. Similarly, ≈10% of patients with lacunar stroke (ie, ischemic stroke as a result of small vessel disease) also have AF. In a second hypothesis, the stroke itself causes AF by affecting central autonomic pathways, possibly when the insula, frontal regions, or the brainstem are affected. However, recent data show no clear relation between specific acute infarct location and poststroke AF, even after adjusting for infarct size. Nevertheless, short, self-limiting AF episodes are observed after hemorrhagic strokes, which are unlikely to have a cardioembolic cause.
In young, fit patients with structurally normal hearts and AF, but no other additional stroke risk factors, the risk of stroke is only mildly increased, indicating that AF alone is not a strong enough risk factor to warrant treatment with anticoagulation. In paroxysmal subclinical AF detected by implanted devices, the temporal relation between AF episodes and first-ever stroke is weak in most cases, and stroke rates are lower than in patients with clinically detected AF, although there is a temporal relation within 5 days of AF shown in one study. The TRENDS study (A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics) and the ASSERT study (Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial) demonstrate that ischemic stroke might occur without episodes of atrial tachyarrhythmias or AF in the past 30 days, and, in many cases, within the 6 months before stroke. AF is often detected only after the occurrence of stroke. However, there does appear to be a relation between the load or burden of subclinical AF and stroke: AF burden >5.5 hours/day or episodes lasting >24 hours are associated with higher first-ever stroke risk. Whether this relation holds true for AF detected after a stroke is not fully understood.

Markers of abnormal atrial tissue substrate and electrical changes are associated with stroke, particularly embolic stroke. This observation indicates that AF may not be the sole or even necessary cause for thromboembolism. Many of the atrial tissue changes predisposing to AF-structural dilatation, myocyte and endothelial dysfunction, fibrosis, and inflammation plausibly play a role in thrombus formation. Thus, left atrial thromboembolism likely involves a complex interplay of systemic cardiovascular risk factors, atrial tissue substrate, and arrhythmia (Figure 1). AF may be a strong marker of atrial myopathy. An exact quantitation of atrial myopathy is not yet available in routine clinical practice. Once AF occurs, it further increases thromboembolic risk by impairing atrial contractile function and blood flow and worsening the underlying atrial myopathy. It has remained difficult to clearly characterize atrial myopathy or define whether it is part of a more generalized cardiomyopathy, in part, related to the complex and heterogeneous etiology of AF. In a 2016 consensus paper, atrial cardiomyopathy was defined as “any complex of structural, architectural, contractile or electrophysiological changes affecting the atria with the potential to produce clinically relevant manifestations,” which applies to AF and stroke.

For all these reasons, the mechanistic relation between AF and stroke requires a more complex theoretical framework. The potential clinical consequences are that it may be possible to tailor the intensity and duration of poststroke AF search by assessing atrial substrate, eg, by echocardiography, electrocardiography.

![Figure 1. Competing and synergistic mechanisms of atrial myopathy and atrial fibrillation in ischemic stroke.](http://ahajournals.org)

RAAS indicates renin-angiotensin-aldosterone system; and TIA, transient ischemic attack.
Key Points 1 and 2

1. AF is a risk factor for thromboembolism and a strong marker for atrial myopathy. In cases of ischemic stroke of uncertain cause, signs of atrial myopathy can be used to inform decisions on the intensity or duration of monitoring for AF.
2. Signs of atrial myopathy without detected AF are not currently sufficient to initiate OAC.

DEFINITIONS: ATRIAL ARRHYTHMIAS AND AF

AF is currently defined as an irregularly irregular rhythm without clear P waves on a surface ECG with a duration arbitrarily designated at ≥30 sec or a standard 12-lead ECG. Whereas computerized ECG interpretation may support preselection of abnormal ECGs, the AF diagnosis should be made or confirmed by a health professional experienced in ECG reading. Shorter episodes have been termed supraventricular or atrial runs, atrial tachycardia, or micro-AF, depending on the rate. The surface ECG can be recorded by standard 12-lead electrocardiography, by precordial or limb leads, by handheld lead 1 rhythm strips, or by wearable devices such as Holter monitors or skin adhesive patches. For implanted cardiac devices that have an atrial lead, AF is detected as atrial high-rate episodes but must be confirmed as being truly AF by the inspection of intracardiac electrograms. Similarly, implantable cardiac monitors (ICMs) produce a single-lead ECG to diagnose AF that must be examined to confirm the diagnosis. Because many of the episodes detected by continuous recorders are silent, these have been termed subclinical AF.

DEFINITIONS: STROKE TYPES AND TIA POTENTIALLY RELATED TO AF, AND MANAGEMENT IMPLICATIONS

Cryptogenic Stroke

Stroke is defined as neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia with symptoms typically lasting >24 hours. The term “cryptogenic stroke” is defined as a stroke for which no probable cause is found, after a thorough diagnostic workup. The definition was later modified in the TOAST trial (Trial of Org 10172 in Acute Stroke Treatment) as a brain infarction that is either not attributable to a source of definite cardioembolism, large artery atherosclerosis, small artery disease, or a defined rare cause of brain infarction in patients with competing stroke etiologies. Unfortunately, the term also includes strokes in patients with incomplete vascular, cardiac, and serologic workup, and patients with competing causes of stroke, as well. AF monitoring has been performed inconsistently in cryptogenic stroke.

Embolic Stroke of Undetermined Source

Embolic stroke of undetermined source (ESUS) is a new term coined in 2014 to provide a more specific definition of a cryptogenic stroke by excluding patients with competing causes or incomplete diagnostic evaluation. ESUS is defined as a nonlacunar brain infarction confirmed by imaging, without hemodynamically relevant stenosis (≥50% lumen diameter reduction) of supply arteries, and without an apparent cardioembolic source as determined by echocardiography and ≥24 hours of ECG monitoring. The reported frequency of ESUS ranges between 9% and 25% of all ischemic strokes, averaging 17%. In general, patients with ESUS are younger and have a lower prevalence of cardiovascular risk factors than patients with non-ESUS ischemic strokes. The average ischemic stroke recurrence rate after ESUS is 4.5% per year, which is comparable to non-ESUS ischemic strokes. According to current guidelines, antiplatelet therapy is recommended for secondary stroke prevention in the majority of patients with ESUS. The ESUS concept has been criticized for including patients with short ECG monitoring duration, thereby potentially encompassing many patients with unknown
AF.\textsuperscript{39} Unfortunately, even in an industrialized country such as Canada, 24-hour Holter ECG monitoring for AF is completed routinely in only a minority of patients with stroke.\textsuperscript{42} As a result of the short duration of ECG monitoring, AF is detected in only 2\% to 3\% of patients following cryptogenic stroke in clinical practice.\textsuperscript{43,44} Studies using prolonged continuous cardiac monitoring have detected AF during follow up in 23\% to 30\% of patients with ESUS.\textsuperscript{41,45} showing that paroxysmal (typically asymptomatic) AF remains undetected in a significant proportion of patients after a stroke. Again, data for this estimate are heterogeneous and not sufficient for a robust number, but it is clear that searching longer and harder and using more sophisticated monitoring will increase detection rates.\textsuperscript{5} Given the high prevalence of asymptomatic paroxysmal AF after ESUS and the established benefits of OAC\textsuperscript{46} for the prevention of AF-related cardioembolic stroke, several clinical trials have been conducted to determine if the use of a non–vitamin K antagonist oral anticoagulant (NOAC) was more effective than aspirin to prevent recurrent stroke, testing the hypothesis that the presumed embolic etiology of ESUS would respond favorably to OAC in comparison with aspirin for the prevention of recurrent stroke.\textsuperscript{47–49} A corollary was that, if a significant proportion of ESUS is related to asymptomatic paroxysmal AF undetected by a 24-hour Holter recording, then recurrent strokes should respond in the same way.

The 2 largest trials, NAVIGATE ESUS (Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients with Recent Embolic Stroke of Undetermined Source) and RE-SPECT ESUS (Dabigatran Etxelitale for Secondary Stroke Prevention in Patients with Embolic Stroke of Undetermined Source),\textsuperscript{50,51} did not show a reduction in recurrent stroke among all patients with ESUS treated empirically with NOAC in comparison with aspirin. NAVIGATE ESUS used a lower daily rivaroxaban dose (15 mg once daily) than the 20 mg once daily dose that is effective in stroke prevention in patients with AF and normal renal function. This may lead to the assumption that recurrent strokes in patients with ESUS could have been prevented better by using the standard dose of rivaroxaban. However, using the standard dose of rivaroxaban would not have lowered the observed bleeding rate. One might argue that the prevalence of undetected AF in the trial was rather low or the risk of ischemic stroke associated with subclinical AF was comparably low. However, analyses are ongoing to explore subgroups of patients with ESUS, in whom a strategy of empiric anticoagulation may be beneficial. A post hoc analysis from NAVIGATE ESUS suggests that patients with an enlarged left atrium (estimated as left atrial diameter >4.6 cm, \(\approx 10\% \) of trial patients) had less recurrent ischemic stroke on rivaroxaban than with aspirin, but this will require prospective confirmation. Although it is plausible that patients with markedly enlarged left atria would be at greatest risk of having or developing AF, it is also postulated that an enlarged left atrium and abnormal left atrial substrate may predispose to atrial thromboembolism in the absence of AF. This concept is being prospectively tested in the ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke), which is enrolling patients with ESUS and either left atrial enlargement, abnormally high P-wave terminal force in ECG lead V\(_1\), or elevated N-terminal pro B-type natriuretic peptide.\textsuperscript{49}

In the RE-SPECT ESUS trial, there was a trend in favor of dabigatran in comparison with aspirin for secondary stroke prevention that developed after 1 year of follow-up, but this was a post hoc exploratory analysis.\textsuperscript{51} In a prespecified secondary analysis, patients >75 years of age appeared to derive greater protection against recurrent stroke with dabigatran (many taking the lower dose of 110 mg twice daily) versus aspirin. However, the overall negative results for the primary outcomes of both NAVIGATE ESUS and RE-SPECT ESUS, may reflect the heterogeneity of underlying embolic sources and composition of emboli (arterial, cardiogenic, or paradoxical),\textsuperscript{50,51} only some of which would benefit from OAC, plus a relatively short average duration of treatment and follow-up in those trials. Better phenotyping may be required to identify subgroups of patients who may benefit from OAC.

The concept of ESUS may thus need a revision and specification of defined subtypes. Anticoagulation may be effective in selected patients without AF but with other evidence of atrial myopathy, although randomized trial evidence for this is currently lacking.\textsuperscript{39} Even if AF detected during poststroke monitoring after ESUS was not the cause for the index stroke, its detection should influence the antithrombotic strategy for prevention of recurrent stroke.

**Key Points 4 and 5**

4. The concept of ESUS has not been proven to identify patients with stroke benefitting from OAC. However, there may be ESUS subgroups (eg, advanced age, significant atrial enlargement) that could benefit more from NOAC therapy than from aspirin.

5. Fulfilling ESUS criteria is neither an indication for NOAC treatment nor for withholding prolonged ECG monitoring.

**Transient Ischemic Attack**

A TIA is defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute infarction according to brain
imaging, with symptoms typically lasting <24 hours. The updated TIA definition encompasses the absence of infarction on brain imaging, because approximately one-third of patients with TIAs, according to clinical criteria, have magnetic resonance imaging–detected diffusion-weighted imaging lesions, indicating ischemic stroke. The diagnosis of TIA is difficult to validate, and TIAs are probably overdiagnosed in clinical practice. TIA has rarely been used as an individual inclusion criterion or study end point in AF randomized trials, limiting available evidence regarding TIA in particular. On the basis of a pooled analysis of the Dutch TIA Trial and Dutch participants of the European Atrial Fibrillation Trial, the risk of vascular events or mortality after TIA or minor stroke is higher in patients with AF than in patients with TIA without AF at enrollment with an adjusted hazard ratio of 1.94 (95% CI, 1.47–2.55) for first stroke. According to a meta-analysis of the randomized European Atrial Fibrillation trial and the Stroke Prevention in Atrial Fibrillation III Trial, the annualized rate of recurrent ischemic stroke was more than halved by using a vitamin K antagonist in comparison with aspirin in patients with TIA and AF. In comparison with patients with AF who have an ischemic stroke (n=551), the annualized rate of recurrent ischemic stroke was lower in patients with AF with TIA (n=222) before enrollment (7% versus 11% using aspirin and 3% versus 4% using anticoagulation, respectively). To date, there is no gold standard of ECG monitoring after TIA, and the precise yield of prolonged monitoring is unknown. Among patients with TIA or minor stroke in the multicenter TIA registry.org project, 9.6% had an AF diagnosis at discharge and 13% had AF after 5 years of follow-up. The proportion of patients with AF increases steeply with age, with a prevalence of >30% in patients ages ≥85 years. A systematic review and meta-analysis revealed a higher rate of AF in selected patients with TIA (including older patients, intensified testing for arrhythmias before enrollment, or presumed cardioembolic/cryptogenic cause), and after prolonged duration of continuous ECG recordings. Although a substantial underdiagnosis of AF in patients with TIA may lead to suboptimal secondary stroke prevention in high-risk patients, caution is needed to avoid unnecessary ECG monitoring in patients with non-specific symptoms mimicking TIA.

WHOM TO MONITOR AFTER A STROKE

Although the minimum recommended monitoring has traditionally been a 24-hour Holter ECG, the requirement for more prolonged ECG monitoring for all patients is under consideration. In unselected survivors of stroke or TIA, 72-hour Holter monitoring was feasible and detected an additional 1.8% of patients with paroxysmal AF in comparison with 2.6% in the first 24 hours. During a median of 64.0 hours, continuous automated stroke unit ECG monitoring detected 92.7% of paroxysmal AF cases in comparison with only 34.1% in 24-hour Holter recordings after ischemic stroke/TIA. Therefore, an extension to 72 hours of continuous rhythm monitoring appears to be justified and “short-term ECG recording followed by continuous ECG monitoring for at least 72 hours” is recommended by current ESC guidelines “in patients with TIA or ischemic stroke” (class I, level B). However, higher costs incurred by prolonged monitoring and the need of logistics for outpatient follow-up have hampered broad application despite demonstration of long-term cost-effectiveness. In particular, in many resource-limited regions, prolonged ECG monitoring may not be feasible, although at least a single time point ECG is feasible and should become a minimal standard. For selection of patients to undergo more intensive monitoring, a number of factors have been proposed. Most rely on either enrichment of AF yield during monitoring, or increase in likelihood that any AF discovered is associated with recurrent stroke. Descriptors include age, demographics, simple clinical risk factors such as heart failure, stroke severity, and ECG, imaging or blood biomarkers, but the most appropriate clinical approach has yet to be precisely defined.

Coexisting Cardiovascular Risk Factors and Prediction of New AF After a Stroke

Old age and heart failure are the most powerful predictors of new AF after ischemic stroke. The CHA2DS2-VASc

Key Point 6

6. Clinically diagnosed AF after a stroke and TIA is associated with a significantly increased risk of stroke or systemic embolism, in particular, in the presence of additional stroke risk factors. Patients with a recent cerebrovascular event and an episode of poststroke AF have not been specifically included in randomized trials, but the AF-SCREEN expert consensus is that OAC therapy (either well-controlled vitamin K antagonist or NOAC) is generally preferred for new AF detected by ECG monitoring after a stroke or TIA.

Key Point 7

7. Patients with ischemic stroke or TIA should have continuous ECG monitoring after a stroke for at least 72 hours.
score and most of its individual components are related to poststroke AF diagnosis.65,68 Prediction of AF detection after a stroke is made more difficult because some risk factors associated with incident AF, such as diabetes mellitus, are more closely associated with noncardioembolic ischemic stroke,69 so diabetes mellitus may actually be associated with a lower risk of finding AF after ischemic stroke.65 In addition, patients with diabetes mellitus may undergo closer clinical scrutiny, so AF may be detected before stroke, contributing to the inverse association.69 Similarly, smoking, which is strongly associated with non-AF ischemic stroke, exhibits an inverse relation with poststroke AF.65,67 Some other characteristics including mitral valve disease or a pacemaker or defibrillator implantation may also increase the likelihood of finding AF.65 However, factors that are more specific for AF as a cause for stroke, such as frequent atrial premature beats, heart failure, B-type natriuretic peptide, and left atrial size or strain, are more likely to be consistent predictors of AF in diverse populations and settings, because they may reflect the atrial myopathy proposed to underlie both AF and cardioembolism.

In clinical practice, a decision to recommend prolonged poststroke ECG monitoring is not based on any established clinical scores, although some have been proposed as being predictive of incident AF.70 Table II in the online-only Data Supplement outlines predictors for AF in the poststroke setting. The studies were performed in populations with stroke and without prior known AF. The data presented for the study by Friberg et al67 have been reanalyzed to include only new cases of AF diagnosed after the stroke event. Figure 2 is a suggested schema for improving poststroke AF monitoring. Indicators of an elevated poststroke AF detection rate after a stroke are summarized in Table 1.

### Brain Imaging

A multifocal pattern of ischemic brain lesions, a wedge-shaped cortical/subcortical pattern, or secondary hemorrhagic transformation on brain imaging, may suggest an embolic origin from the heart or the aortic arch.71 In contrast to hemorrhagic stroke, which has no underlying brain ischemia, secondary hemorrhagic transformation of an ischemic stroke occurs after reperfusion, and is more frequently observed in patients with AF. However, in a post hoc analysis of the CRYSTAL AF study (Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke), the detection of a first episode of AF did not correlate with brain lesion pattern.17 Although the likelihood of AF detection is comparatively low in patients with a lacunar stroke type, ≈10% of patients with presumed lacunar stroke have AF.16 This is sufficient to recommend a minimum duration of poststroke ECG monitoring in such patients.

### Cardiac Imaging

Left atrial enlargement,72,73 valvular abnormalities (in particular, rheumatic mitral valve stenosis or severe mitral and tricuspid valve insufficiency), and spontaneous echocardiographic contrast or solid thrombi in the atrium may be predictive of the development of AF after a stroke.20 In addition, left atrial volume index in combination with atrial function has been demonstrated to be predictive for detection of AF,74 as has low atrial strain, which provides independent risk stratification for the development of AF.

---

**Figure 2. Algorithm for intensified atrial fibrillation monitoring in ischemic stroke.**

High atrial fibrillation risk refers to several indicators shown in Table 1. Dashed lines indicate that additional rhythm monitoring could be considered. The color shading correlates with the strength of evidence (least evidence in light blue color). Right hand arrow indicates the relation between atrial fibrillation yield and time after a stroke that monitoring is commenced.
of new AF over clinical markers. It remains to be established whether the morphology of the left atrial appendage itself, which has been related to thromboembolic risk, is a relevant predictor of AF detection after a stroke.

Electrocardiogram

The presence of atrial runs (lasting <30 sec) and excessive supraventricular ectopic activity are associated with an increased probability of AF detection after a stroke. Atrial runs also increase the risk of recurrent stroke. An algorithm for ECG monitoring has been proposed based on the presence of frequent or infrequent atrial premature beats. P-wave characteristics including P-wave axis, duration, terminal force, and dispersion, may be predictors of intermittent AF.

Biomarkers

The predictive value of N-terminal pro B-type natriuretic peptide or B-type natriuretic peptide measurement for AF detection has been highlighted in several stroke cohorts. In addition, elevated C-reactive protein, and troponin levels, as well, are related to the AF detection rate after a stroke. These biomarkers are nonspecific predictors, being elevated in various comorbidities (cardiac and noncardiac) and are predictive of various cardiovascular and noncardiovascular outcomes.

HOW TO MONITOR: METHODS AND CLINICAL SIGNIFICANCE OF DETECTED AF

Monitoring methods for AF vary according to the device used for ECG recording, quality of ECG signal, number of leads available, duration and interval of monitoring, time of commencement of recording after a stroke, invasiveness of the procedure, and methodology and software for rhythm analysis (Table I in the online-only Data Supplement). Technological advances have produced novel devices that may improve the feasibility, patient comfort, and cost-effectiveness of monitoring for AF. In Figure 3, a wide spectrum of devices and methods for AF search are illustrated from blood pressure monitors and handheld devices that can be used by a healthcare provider or in a patient-activated intermittent rhythm-monitoring strategy, to wearable, nonadhesive dry-electrode belts, adhesive patch devices, and implantable loop recorders that provide continuous ECG recordings of variable durations. A full exposition of available monitoring devices is beyond the scope of this white paper, and is available in a recent review by Zungsontiporn and Link.

Oscillometric devices to measure blood pressure or smartphone photoplethysmographic methods permit the detection of an irregular pulse using proprietary algorithms. To confirm a diagnosis of AF, however, these devices require an ECG rhythm strip, which is currently a significant limitation. Similarly, smartwatches and fitness trackers are capable of determining AF from pulse irregularity, and have a similar limitation. Some smartwatch applications can monitor pulse regularly continuously when the watch is being worn, and even notify the patient if possible AF is detected. If an ECG is built into the device (eg, Kardia Band and Apple Watch Series 4), a patient-activated rhythm strip can also be recorded when a warning is sent by the watch. If the devices do not provide a confirmatory ECG rhythm strip, an additional ECG is required for AF confirmation as was the case in the Apple Heart Study. Because of the increasing availability of smartphones and smartwatches, even in patients after a stroke, they may become an attractive alternative to classical ECG rhythm monitoring for prolonged AF search. For smartphone-based or other handheld devices providing an ECG rhythm strip recording, requested by health professionals, or even by patient-activated intermittent recordings, feasibility has been shown; however, the validity of algorithms, the accuracy of AF detection, and noninferiority in comparison with classical devices for prolonged ECG monitoring for rhythm analysis (Table I in the online-only Data Supplement).
monitoring needs to be demonstrated for smartwatch ECG techniques in studies after a stroke. Low-noise, high-quality signals are necessary for the automated algorithms to perform well, which is critical, in particular, when devices are used in elderly patients after a stroke with neurological deficits. Therefore, the place of smartwatches with or without inbuilt ECGs in the poststroke setting remains to be determined.

Table I in the online-only Data Supplement gives an overview of studies in poststroke populations with different monitoring methods and the yield of AF. Direct comparison between the methods is difficult for the following reasons:

1. Poststroke AF prevalence in certain subgroups (eg, cryptogenic stroke, ESUS, large artery atherosclerosis, non-AF cardiac source) may be higher than in others (eg, lacunar stroke) and selection of subgroups will have an impact on AF detection rate.

2. Greater efforts made to detect AF during hospitalization after acute ischemic stroke will lower the yield of new AF on ECG monitoring postdischarge.84

3. The earlier AF monitoring starts after stroke onset, the higher the yield of a first episode of AF.

4. The longer and more continuous the monitoring postdischarge, the higher the yield of new AF.

5. Quality of ECG analysis relates to AF detection rates.

For poststroke AF search, a combination of different approaches, eg, noninvasive cumulative 72-hour monitoring in all patients, and more prolonged monitoring in patients with increased risk of AF, has been proposed.20 Some studies have used a staged approach to monitoring, with initial resting ECG, followed by Holter monitoring in patients free of AF and then an ICM if these are negative. Other approaches use a longer duration of intermittent patient-activated or even nurse-activated monitoring, which may represent a compromise.83 AF can be detected in up to one-quarter of patients after a stroke if all the phases of ECG surveillance are included.5

Extended Continuous or Intermittent Monitoring Other Than 24-Hour Holter Recordings

The Find-AF randomized trial85 (Finding Atrial Fibrillation in Stroke: Evaluation of Enhanced and Prolonged Holter Monitoring) analyzed patients with stroke aged ≥60 years presenting with sinus rhythm and without history of AF randomly assigned to standard care (at least 24 hours of rhythm monitoring), or 10-day Holter ECG at baseline, 3 months and 6 months after the index stroke, with the second and third Holter being performed in 68% and 65% of patients without prior AF diagnosis who remained in the study. The overall value of this monitoring method was similar across the whole spectrum of stroke etiology, with 14% new AF versus
5% in the control arm at 6 months. During extended follow-up between 6 and 36 months, the control arm almost caught up, with significantly more new AF cases than in the intervention arm, indicating that short-term monitoring detects AF cases that would otherwise be diagnosed later. Guideline adherence, with 24-hour Holter monitoring performed as usual care in 91.4% of the control arm, was very high in comparison with other studies. A trend for stroke risk reduction was observed with the intensified monitoring strategy. A large-scale randomized study that is based on this protocol is planned, with recurrent stroke as the end point.

**Outpatient Cardiac Telemetry**

Mobile cardiac outpatient telemetry was designed for arrhythmia monitoring in patients outside the hospital setting. New or silent AF discovered by short-term outpatient monitoring ranges from 0% to 24% over a variable length of follow-up (Table I in the online-only Data Supplement). The detection of an episode of AF in some of these studies is as short as 5 to 30 sec in duration, which is below the currently accepted definition of AF duration, although recent observational studies indicate that the risk of clinical AF is high among subjects with AF episodes <30 sec (micro-AF). A common observation in these studies was that a significant proportion did not complete the recommended monitoring course.

**ICM, Long-Term Wearable Devices, and Intermittent Recordings**

ICMs usually detect AF by analyzing the irregularity and incoherence of successive R-R intervals. Consequently, ICMs require a minimum amount of time, typically 2 minutes, over which rhythm evidence is accrued and analyzed. Data from several studies using ICMs after cryptogenic stroke are presented in Table I in the online-only Data Supplement. AF incidence ranges from 16% to 33.7% depending on the definition of episode duration, the duration of monitoring, and the amount of monitoring performed before device implantation.

Two pivotal randomized studies explored long-term monitoring versus shorter-term monitoring after cryptogenic stroke; CRYSTAL-AF compared ICM versus standard of care in 441 patients (aged ≥40 years) within 90 days of cryptogenic stroke, and EMBRACE (30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event) studied a 30-day wearable monitor versus a repeat 24-hour Holter in 572 patients (aged ≥55 years) with a cryptogenic stroke or TIA within the last 6 months. Both studies showed that long-term monitoring is significantly more sensitive than standard arrhythmia monitoring for AF identification.

In the CRYSTAL-AF study, AF defined as >30 sec was detected in 8.9%, 12.4%, and 30.0% patients in the ICM arm and 1.4%, 2.0%, and 3.0% patients in the standard-of-care monitoring arm at 6, 12, and 36 months, respectively. At the 12-month analysis, the median time from randomization to AF detection in the ICM arm was 84 days, with 79% of these episodes asymptomatic. At 36 months, AF was detected in 30.0% in the patients with ICM versus 3.0% of the control group. Ambulatory monitoring in the control arms of CRYSTAL-AF was at the discretion of the treating physician and resulted in very limited ECG rhythm monitoring: <30% of patients received conventional ECGs, and <10% received 24-hour Holter monitoring. In the EMBRACE study, unlike CRYSTAL-AF, transesophageal echocardiography or intracranial vascular imaging was not required as part of the stroke workup. The primary end point (detection of AF ≥30 sec within 90 days) was met in 16.1% and 3.2% of patients in the event recorder versus control arms, respectively, with AF ≥2.5 minutes (secondary end point) in 9.9% and 2.5%, respectively, indicating that one-third of the episodes detected were very brief.

The duration or burden of episodes of subclinical AF relevant for an elevated stroke risk is currently debated, and may need to be corrected for the duration of the monitoring period. From studies of implanted devices in patients without a prior stroke, a dose-response association exists between AF duration or burden and the subsequent risk of stroke, but there is a significant dynamic process of transition from lower to higher AF burden, determined principally by the burden of first-detected AF episodes. The implications of high versus low burden of AF detected by continuous monitoring may differ in patients after a stroke. In the absence of evidence, there is consensus among experts to treat as significant any episode of AF ≥30 sec detected by continuous monitoring after a stroke, and prescribe anticoagulant prophylaxis. However, the finding of similar yield of new AF on ICMs in patients with no stroke history (ASSERT II [Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor], REVEAL-AF [Incidence of AF in High Risk Patients], and PREDATE-AF [Predicting Atrial Fibrillation or Flutter]) to that seen in CRYSTAL-AF post–cryptogenic stroke, requires some rethinking of the implications of prolonged continuous ECG monitoring after a stroke, and whether
the threshold of AF burden for basing a therapeutic decision differs between the 2 populations.

MANAGEMENT CHANGES WHEN AF IS DETECTED AFTER A STROKE

The EMBRACE and CRYSTAL-AF trials indicate that AF detection changes the treatment from antplatelet to OAC therapy in most patients with cryptogenic stroke: OAC use increased from 5% to 10% to almost 97% following AF detection, although this may not apply to healthcare settings outside trials. An important limitation of the CRYSTAL-AF and EMBRACE trials is that they were not designed to demonstrate an improvement in poststroke outcome from prescription of OAC to patients with detected AF, but rather, they were set up to determine AF detection rate with prolonged or continuous monitoring. In the Find-AF randomized trial, all patients with detected AF were switched from antplatelet to OAC therapy, and 1 year after randomization, 97% remained on anticoagulation when sexless CHA2DS2VASc score is

suggested, multiple randomized trials are ongoing.

POTENTIAL HARMs OF MONITORING

There are several reasons why monitoring for AF after a stroke might potentially cause harm. Table III in the online-only Data Supplement summarizes potential reasons for harms and possible methods to counteract each harm. Most harms result from overtreatment with OAC and the potentially fatal side-effects of OAC-related bleeding. As in clinical AF in patients without prior stroke, a risk-benefit assessment of OAC should be considered for each patient. This certainly favors anticoagulation when sexless CHA2DS2VASc score is ≥2. Because the CHA2DS2VASc score gives 2 points for a prior stroke or TIA, the net clinical benefit would be expected to be positive for patients with prior stroke or TIA, and AF, because all have a score of at least 2. Another harm is that AF monitoring procedures and additional medical workup could result in unnecessary further tests and use of healthcare resources. To reduce these potential harms, the population that should undergo monitoring, in particular, more intensive continuous monitoring, should be carefully defined, and continuous quality control of the monitoring procedures instituted. Appropriate patient information about potential discomfort with ECG monitoring, and emphasizing the need for anticoagulation in case of AF detection, is necessary at the time of initiating monitoring. If AF was missed during monitoring or the ECG misinterpreted, patients with AF may not seek medical attention if AF becomes symptomatic, because the negative monitoring could provide a false sense of security. If the harms of untreated AF detected during monitoring or the benefit of AF treatment have been overestimated, this would also distort the risk-benefit of monitoring for poststroke AF. Data from a large UK data set of 5555 ambulatory asymptomatic patients with incidentally detected AF (of whom 9.2% had prior stroke) suggest that the risk of stroke at 3 years is similar to that of symptomatic or hospitalized patients with AF, providing the rationale for clinical monitoring in specific settings, such as after a stroke, with prescription of oral anticoagulation in patients with AF detected during monitoring.

PATIENT PERSPECTIVE

Although patients, in general, are strongly supportive of detection of AF after a stroke, consideration needs to be given to comfort of the chosen detection strategy, and to subsequent potential referral and treatment recommendations, as well, if AF is detected. Although ambulatory Holter ECG monitoring is widely available, poor patient compliance can occur, attributable, in part, to the bulky size and wired connections to leads. This is a particular issue if Holter recordings are continued over a number of days. Skin preparation for ECG monitoring can be abrascive and irritating, and adhesives can cause allergic reactions, again more of an issue for wearable recorders used over a number of days. In a systematic review of patient preference for monitoring, it was noted that any chosen monitoring device should be compact and simple to operate and maintain. The monitoring devices should not affect daily behavior such as showering. Although patient preference for treatment is of paramount importance, patient involvement in choice of monitoring strategy rarely occurs, yet this may be a key factor in patient compliance.

HEALTH-ECONOMIC ASSESSMENTS

In the absence of randomized trial evidence, all health-economic studies rely on assumptions of benefit of OAC treatment for AF discovered after a stroke. This is the main caveat of cost-effectiveness calculations.

A meta-analysis of 4 studies of prolonged Holter monitoring (2–21 days) following routine poststroke telemetry, found an incidence of detected AF 4.9% to...
7.7% and a calculated incremental cost-effectiveness ratio (ICER) of $13 000 per quality-adjusted life-years (QALY) gained by identifying patients who benefit from anticoagulation. A comparison of 24-hour Holter with 7-day Holter monitoring found that the longer period was associated with greater cost-benefit (ICER €8354/QALY). Prescreening with transthoracic echocardiography added no additional cost-benefit. Intermittent ECG monitoring using a handheld device for 10 sec twice daily for 30 days was found more cost-effective (ICER €6458/QALY) than 24-hour Holter monitoring.

Although longer duration of continuous monitoring increases AF detection, cost-effectiveness needs to balance this against the increased cost of the devices, implantation, and device monitoring, and the possibility that short episodes detected late after a stroke on continuous recordings do not carry the same risk. In a cost-effectiveness analysis of the EMBRACE trial, a strategy of 30-day noninvasive monitoring appeared cost-effective with an ICER of $2000/QALY in comparison with an additional 24-hour Holter. The 7-day or 14-day ECG monitoring was cost saving and more effective than an additional 24-hour Holter in this analysis. The CRYSTAL-AF study comparing an ICM against usual standard of care (ECG and 24-hour Holter monitoring) found an ICER of £17175/QALY. The CRYSTAL-AF analysis assumed a number needed to implant to prevent one stroke of ≈20, which may be optimistic, and does not take into account the low use of conventional or Holter recorders in the control arm. It is notable that both NAVIGATE ESUS and EMBRACE analyses recruited patients on average >1 month from stroke onset. It is arguable that less prolonged, less expensive monitoring techniques may have more easily detected patients at an earlier time point where cardioembolic risk from the AF may be higher, and this would impact health-economic comparisons of different ECG monitoring strategies.

**CURRENT GUIDELINE RECOMMENDATIONS**

ECG monitoring for AF is recommended in national and international guidelines on poststroke care (Table IV in the online-only Data Supplement). Apart from a baseline ECG, guidelines remain vague regarding length and type of monitoring and direction as to which patients should undergo more intensified monitoring. The broadest indication for monitoring is given by the 2016 European Society of Cardiology AF guidelines that recommend AF monitoring for 72 hours in all patients with ischemic stroke without known AF. The American Heart Association guidelines state that, for patients with TIA or ischemic stroke and AF detected by ECG at the time or within 24 months preceding the presentation, OAC begins within 3 months is deemed superior to aspirin for the prevention of vascular death, stroke, myocardial infarction, and systemic embolism, and is therefore recommended. The recommendation is based on 225 patients of whom 78% had persistent/permanent AF and 22% paroxysmal AF. For eligibility, AF had to be documented on ECG at admission, or in the case of paroxysmal AF, within the previous 24 months. The guidelines designate class IB level of evidence. The Canadian stroke best practice recommendations suggest prolonged ECG monitoring for at least 14 days in selected patients with ischemic stroke/TIA of undetermined source in whom a cardioembolic mechanism is suspected and who would be amenable to OAC. They assign an evidence level A. In general, guidelines focus on the detection of AF rather than the yield of AF from the monitoring technique. The American College

<table>
<thead>
<tr>
<th><strong>Table 2. Key Knowledge Gaps in Searching for Atrial Fibrillation After a Stroke</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathophysiological role of AF detected poststroke: how to determine whether this is a cause of the index stroke, or a bystander, and its association with recurrent cardioembolism.</td>
</tr>
<tr>
<td>Determine threshold of AF burden poststroke relative to ECG monitoring intensity and duration, associated with an increased risk of recurrent cardioembolic stroke requiring anticoagulation, and the relationship of increased risk with timing of ECG monitoring commencement after stroke.</td>
</tr>
<tr>
<td>Determine the persistence and recurrence rate of paroxysmal AF first detected in the acute phase of stroke.</td>
</tr>
<tr>
<td>Define whether atrial myopathy/cardiomyopathy increases recurrent stroke risk independent of AF. This requires definition, quantitation, and validation of atrial myopathy markers, eg, atrial enlargement, atrial ectopy or P-wave morphology, functional imaging, and elevation in blood biomarkers such as NT-proBNP. Test use of these markers prospectively to tailor type, intensity, and duration of ECG monitoring for AF detection, and effect of empiric antithrombotic treatment (as in the ARCADIA study).</td>
</tr>
<tr>
<td>Identify predictors of poststroke AF that could be used to tailor intensified monitoring.</td>
</tr>
<tr>
<td>Identify ESUS subgroups with increased cardioembolic risk likely to benefit from empiric OAC treatment without ECG monitoring for AF, and test prospectively.</td>
</tr>
<tr>
<td>Define the most effective method, intensity, and duration of rhythm monitoring after ischemic stroke to detect clinically relevant AF.</td>
</tr>
<tr>
<td>Define and validate the most cost-efficient method for poststroke AF monitoring in a variety of healthcare systems including those with limited resources and limited access to vitamin K antagonist monitoring and NOACS.</td>
</tr>
<tr>
<td>Develop pathways and structures for widespread implementation of searching for AF in stroke units and in poststroke care tailored to country-specific resources and requirements.</td>
</tr>
</tbody>
</table>

AF indicates atrial fibrillation; ARCADIA, Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke; ESUS, embolic stroke of undetermined source; NOAC, non–vitamin K antagonist oral anticoagulant; NT-proBNP, N-terminal pro B-type natriuretic peptide; and OAC, oral anticoagulation.
of Chest Physicians 2018 antithrombotic AF guidelines have no specific recommendation but discuss continued cardiac evaluation (eg, prolonged rhythm monitoring) for patients with ESUS. The Australian Heart Foundation and Cardiac Society of Australia and New Zealand 2018 guideline recommends that, for patients with ESUS, longer-term ECG monitoring (external or implantable) should be used, whereas the 2019 American Heart Association/American College of Cardiology/Heart Rhythm Society update of the 2014 guideline states that ICM implantation is reasonable to optimize detection of silent AF, in patients with cryptogenic stroke in whom external ambulatory monitoring is inconclusive.

CONCLUSIONS

In the absence of a prior history of the arrhythmia, AF can be detected by ECG monitoring in approximately one-quarter of all patients with acute ischemic stroke by routine monitoring followed by an intensified or prolonged AF search. It may be the cause of the index stroke, a bystander, particularly in older patients with high cardiovascular comorbidity and risk factor burden; or a neurogenically induced, secondary consequence of stroke. Atrial myopathy may play a role in thromboembolic risk and is an indicator of increased poststroke AF detection rate on ECG monitoring. Monitoring for AF poststroke/TIA requires an ECG-based diagnosis. A minimum duration of 72 hours of cumulative ECG recording should follow ischemic strokes in patients who do not have a prior AF diagnosis. Longer periods of continuous monitoring will detect more AF cases, and a number of factors could be used to determine the selection of patients for more intensive monitoring. Whether the duration or burden of AF increases the risk of recurrent stroke is debated and is a key knowledge gap (Table 2); nevertheless, OAC treatment is often prescribed for any AF episode ≥30 sec. At present, there is no evidence supporting initiation of OAC therapy in patients with markers of atrial myopathy or with cryptogenic stroke or ESUS. The diagnosis of AF after a stroke should lead to changes in clinical workup, and usually, institution of OAC therapy. There are a number of knowledge gaps summarized in Table 2. In particular, further evidence is needed to establish risk-stratified ECG monitoring strategies that are safe, effective, and cost-effective.

ARTICLE INFORMATION

The online-only Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.119.040267.

Authors

Renate B. Schnabel, MD, MSc; Karl Georg Haeusler, MD; Jeffrey S. Healey, MD, MSc; Ben Freedman, MBBS, PhD; Giuseppe Boriani, MD; Johannes Brachmann, MD; Axel Brandes, MD, DMSc; Alejandro Bustamante, MD, PhD; Barbara Casadei, MD, DPhil; Harry J.G.M. Crinjs, MD; Wolfram Doehner, MD, PhD; Gunnar Engstroem, MD, PhD; Laurent Fauchier, MD; Leif Friberg, MD; David J. Gladstone, MD, PhD; Tayo V. Glotzer, MD; Shinya Goto, MD; Graeme J. Hankey, MD; Joseph A. Harbison, MD; F.D. Richard Hobbs, MD; Linda S.B. Johnson, MD, PhD; Hoorn Kamel, MD; Paulus Kirchhof, MD; Eleni Korompoki, MD, PhD; Dirk W. Krieger, MD, PhD; Gregory Y.H. Lip, MD; Maja-Lisa Lachen, MD; Georges H. Marresse, MD; Joan Montaner, MD, PhD; Lis Neubeck, PhD; George Ntaios, MD, MSc; Jonathan P. Piccini, MD, MHS; Tatjana S. Potpara, MD, PhD; Terence J. Quinn, MD; James A. Reiffel, MD; Antonio Luz Pinho Ribeiro, MD, PhD; Michel Rienstra, MD, PhD; Märtten Rosenqvist, MD, PhD; Sakis Themistoklakis, MD; Moritz F. Sinner, MD, PhD; Michiel Rienstra, MD, PhD; Michiel Rienstra, MD, PhD; Märtten Rosenqvist, MD, PhD; Sakis Themistoklakis, MD; Moritz F. Sinner, MD, PhD; Jesper Hanstrup Swendsen, MD, DMSc; Isabelle C. Van Gelder, MD, PhD; Rolf Wachter, MD; Tissa Wijeratne, MD; Bernard Yan, DMEDsc

Correspondence

Ben Freedman, MBBS, PhD, Heart Research Institute, Level 3E, Charles Perkins Centre, University of Sydney, NSW 2006 Australia. Email ben.freedman@sydney.edu.au

Affiliations

University Heart Centre, Hamburg, Germany; German Cardiovascular Research Center (DZHK), Partner Site Hamburg/Kiel/Lübeck (R.B.-S.). Department of Neurology, Universitätsklinikum Würzburg, Germany (K.G.H.). Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (J.S.H.). Heart Research Institute, Charles Perkins Centre, and Concord Hospital Cardiology, University of Sydney, Australia (B.F.). Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena University Hospital, Italy (G.B.). Klinikum Coburg, Germany (J.B.). Odense University Hospital, Denmark (A. Brandes). Neurovascular Research Laboratory, Institut de Recerca, Hospital Universitari Vall d’Hebron (VHIR), Barcelona, Spain (A. Bustamante, J.M.). Division of Cardiovascular Medicine, British Heart Foundation Centre for Research Excellence, NIHR Oxford Biomedical Research Centre (B.C.), Nuffield Department of Primary Care Health Sciences, Harris Manchester College (F.D.R.H.), University of Oxford, United Kingdom. Department of Cardiology, Maastricht University Medical Center, the Netherlands (H.I.G.M.C.). Department of Cardiology (Vircow Klinikum), German Centre for Cardiovascular Research (DZHK), partner site Berlin, and BHI Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Germany (W.D.). Department of Clinical Sciences, Lund University, Malmö, Sweden (G.E., L.J.). Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Université François Rabelais, Tours, France (L.F.). Karolinska Institute, Stockholm, Sweden (L.F., M. Rosenqvist). Department of Medicine, University of Toronto; and Hurvitz Brain Sciences Program and Regional Stroke Centre, Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto, Canada (D.J.G.). Hackensack University Medical Center, NJ (T.G.). Tokai University School of Medicine, Metabolic and Nutritional Research Center, Shizuoka, Japan (S.G.). Medical School, The University of Western Australia, Perth; and Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.). Trinity College, Medical Gerontological, Dublin, Ireland (J. Harbison). Division of Cardiology, McMaster University; Arrhythmia Services, Hamilton Health Sciences; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (J. Healey). Weill Cornell Medical College, New York, NY (H.K.). Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom; Sandwell and West Birmingham Hospitals and University Hospitals Birmingham NHS trusts, United Kingdom; AFNET, Muenster, Germany (P.K.). Division of Brain Science, Imperial College London, United Kingdom (E.K.). Mohammed Bin Rashid University, Dubai, United Arab Emirates; and Neurosciences, Mediclinic City Hospital, Dubai, United Arab Emirates (D.W.K.). Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, United Kingdom (G.Y.H.L.). University Hospital of North Norway, Department of Cardiology, Tromsø (M.-L.L.). Cliniques du Sud Luxembourg, Arlon, Belgium (G.H.M.). Edinburgh Napier University, United Kingdom (L.N.). Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece (G.N.). Duke University Medical Center; and Duke Clinical Research Institute, Durham, NC (J.P.). Internal Medicine/Cardiology, School of Medicine, University of Belgrade, Serbia (T.S.P.). University of Glasgow, Institute of Cardiovascular and Medical Sciences, University of Glasgow (T.Q.). Department of Medicine, Division of Cardiology, Columbia University, New York, NY (J.A.R.). Internal Medicine Department, School of Medicine, Federal University of Minas Gerais (UFMG); Hospital das Clínicas, UFMG, Belo Horizonte, Brazil (A.L.P.R.). Department of Cardiology, University.
of Medicine and is principal investigator of the EMRACE (30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event) and SCREEN-AF (Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older: the SCREEN-AF Randomized Trial) trials, medical monitor for the ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke), and site principal investigator and co-chair of a NAVIGATE EUS trial (Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients with Recent Embolic Stroke of Undetermined Source) subgroup analysis working group. Dr Goto reports research support from Sanofi, Pfizer, Ono, the Ministry of Education, Culture, Sports, Science and Technology (MEXT)/Japanese Society for the Promotion of Science (JSPS) KAKENHI 17K19669 and partly by 18H01726 and the Nakatani Foundation. Prof Hankey reports personal honoraria from Bayer, Bristol-Myers Squibb, Medscape, and the American Heart Association. Dr Hobbs reports occupational funding for speaking or consulting. Dr Johnson reports research support from governmental funding in the Swedish National Health Service and by the Swedish Heart and Lung Foundation. Dr Kamel reports research support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (grants R01NS079443, U01NS095869, and U01NS106513) and serves as a steering committee member of Medtronic’s Stroke AF trial, receives in-kind study drug from BMS-Pfizer and in-kind study assays for the ARCADIA trial, and has served on an advisory board for Roivant Sciences. Dr Kirchhof reports research support from the European Union (grant agreement number 633193 (CATCH ME [Characterizing Atrial fibrillation by Translating its Causes into Health Modifiers in the Elderly]), the British Heart Foundation (F/13/3/30324), the Medical Research Council (United Kingdom), the DZHK (German Cardiovascular Research Center, partner site: Munich Heart Alliance, Munich, Germany) and serves as a steering committee member of Medtronic’s Stroke AF trial, receives in-kind study drug from BMS-Pfizer and in-kind study assays for the ARCADIA trial, and has served on an advisory board for Roivant Sciences. Dr Korompoki reports advisory board fees from Pfizer and lecture fees from Amgen, Bayer, and Pfizer. Dr Lip reports lecture fees from Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi Sankyo (no fees directly received personally) and is a consultant for Bayer/Janssen; BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Daiichi Sankyo, and Sanofi. Dr Gladiali reports personal honoraria from Bayer, Boehringer Ingelheim, and Daiichi Sankyo, outside the submitted work. Dr Neubeck reports fees for participation in meetings from Pfizer/BMS. Dr Ntaios reports lecture fees/advisory board and research support from BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi Sankyo and nonfinancial support from Bayer, and travel support or lecture fees from Bayer, BMS, and Pfizer. Dr Reiffel reports research support from Medtronic and Janssen and is a consultant for Medtronic, Johnson & Johnson, Portola, Acesion, Incardia Therapeutics, and Roivant. Dr Ribeiro reports research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil; grants 46551/2014-1 and 303526/2016-8) and by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Brazil; PPM-00422-17). Dr Rienstra and van Gelder reports research support from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, CVON 2014-9: Reappraisal of Atrial Fibrillation: interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of Atrial Fibrillation (RACE V). Dr Svendsen reports to be a member of Medtronic advisory boards and to have received speaking honoraria and research grants from Medtronic, in addition to research grant from Gilead. Dr Rosenqvist reports consultancy and lecture fees from Medtronic, Zenicor, Bayer, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, and Abbott and support grants from Roche Diagnostics, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, and Bayer. Dr Sinner reports research support from the European Commission’s Horizon 2020 research and innovation program (grant agreement no. 633196 CATCH-ME). Dr Wachter reports research support from BMBF (Bundesministerium für Bildung und Forschung), DFG (Deutsche Forschungsgemeinschaft), and Boehringer Ingelheim as well as lecture fees outside the submitted work from Bayer, BMS, Boehringer Ingelheim, Daichi, Medtronic, and Pfizer. All other authors report no disclosures.

REFERENCES


Circulation. 2019;139:1834–1850. DOI: 10.1161/CIRCULATIONAHA.119.040267

November 26, 2019 1849
88. State of the art. Searching for Atrial Fibrillation After a Stroke. 2019;140:1834–1850. DOI: 10.1161/CIRCULATIONAHA.119.040267
89. Schnabel et al.